Colchicine Ineffective in Long COVID
Colchicine Ineffective in Long COVID jjcush@gmail.com Tue, 10/21/2025 – 14:20
RheumNow
October 2025
ClinicalTrials.gov
Teleconsultation Approach to CTD-ILD Care Delivery in Rural UnderServed CommuniTies (TRUST Initiative)
Conditions: Interstitial Lung Disease Due to Systemic Disease (Disorder); Interstitial Lung Disease in Patients With Rheumatoid Arthritis; Interstitial Lung Disease
ClinicalTrials.gov
A Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases
Conditions: Systemic Lupus Erythematosus; Idiopahic Inflammatory Myopathies; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Sjögren’s Syndrome; Antiphospholipid Syndrome; Immune Thrombocytopenia; Systemic Sclerosis Interventions:
ClinicalTrials.gov
Teleconsultation Approach to CTD-ILD Care Delivery in Rural UnderServed CommuniTies (TRUST Initiative)
Conditions: Interstitial Lung Disease Due to Systemic Disease (Disorder); Interstitial Lung Disease in Patients With Rheumatoid Arthritis; Interstitial Lung Disease
ClinicalTrials.gov
A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
Conditions: Arthritis, Rheumatoid Interventions: Drug: Tulisokibart; Drug: Placebo; Drug: Methotrexate Sponsors: Merck Sharp & Dohme LLC Recruiting
ClinicalTrials.gov
A Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases
Conditions: Systemic Lupus Erythematosus; Idiopahic Inflammatory Myopathies; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Sjögren’s Syndrome; Antiphospholipid Syndrome; Immune Thrombocytopenia; Systemic Sclerosis Interventions:
ClinicalTrials.gov
A Study of SPY072 in Rheumatic Disease
Conditions: Rheumatoid Arthritis; Psoriatic Arthritis; Axial Spondyloarthritis; Rheumatic Diseases; Rheumatic Joint Disease; PsA (Psoriatic Arthritis); AxSpA; Rheumatologic Disease Interventions: Drug:
ClinicalTrials.gov
A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
Conditions: Arthritis, Rheumatoid Interventions: Drug: Tulisokibart; Drug: Placebo; Drug: Methotrexate Sponsors: Merck Sharp & Dohme LLC Recruiting
ClinicalTrials.gov
A Study of SPY072 in Rheumatic Disease
Conditions: Rheumatoid Arthritis; Psoriatic Arthritis; Axial Spondyloarthritis; Rheumatic Diseases; Rheumatic Joint Disease; PsA (Psoriatic Arthritis); AxSpA; Rheumatologic Disease Interventions: Drug:
ClinicalTrials.gov
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
Conditions: Rheumatoid Arthritis Interventions: Drug: Afimkibart; Drug: Placebo Sponsors: Hoffmann-La Roche Not yet recruiting
ClinicalTrials.gov
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
Conditions: Refractory Autoimmune Diseases Interventions: Genetic: BMS-986515; Drug: Fludarabine; Drug: Cyclophosphamide; Drug: Tocilizumab Sponsors: Juno Therapeutics, Inc., a Bristol-Myers Squibb
ClinicalTrials.gov
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
Conditions: Refractory Rheumatoid Arthritis (RA); Idiopathic Inflammatory Myopathies (IIMs); Systemic Sclerosis (SSc); Rheumatoid Arthritis (RA; IIM; Myositis; Scleroderma; Sjogren Syndrome;
ClinicalTrials.gov
Study of GS-0151 in Participants With Rheumatoid Arthritis
Conditions: Rheumatoid Arthritis Interventions: Drug: GS-0151; Drug: Placebo Sponsors: Gilead Sciences Recruiting
ClinicalTrials.gov
A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis
Conditions: Rheumatoid Arthritis Interventions: Drug: LY3541860 Sponsors: Eli Lilly and Company Recruiting
ClinicalTrials.gov
A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis
Conditions: Rheumatoid Arthritis Interventions: Drug: IMVT-1402; Drug: Placebo Sponsors: Immunovant Sciences GmbH Recruiting
Google News
Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American … – Taiwan News
Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American College of Rheumatology (ACR) Convergence. GlobeNewswire Oct. 21, 2025
RheumNow
30% of RA pts have non-alcoholic fatty liver disease (NAFLD). In 170 pts on MTX or biologics (TNFi, IL-6i)- NAFLD was fo
30% of RA pts have non-alcoholic fatty liver disease (NAFLD). In 170 pts on MTX or biologics (TNFi, IL-6i)- NAFLD
Google News
Lupus Research Alliance Showcases Research that will Shape Next Generation Treatments …
… Rheumatology, to demonstrate how its unique impact across the full research continuum is shaping the next generation of treatments
Google News
Dual evaluation of Citrulluscolocynthis fruit extract for anti-rheumatic activity – ResearchGate
Request PDF | Dual evaluation of Citrulluscolocynthis fruit extract for anti-rheumatic activity: integrating in silico docking and in vivo murine …
Google News
Rheumatologist joins Meritus – Franklin County Free Press
Meritus Health is pleased to welcome Mary R. Romanic, M.D., to Meritus Rheumatology. She is now seeing patients two days
RheumNow
Bad Actor Cofactor (10.17.2025) Dr. Jack Cush reviews the news and journal reports, discusses pediatric reports, pregn
Bad Actor Cofactor (10.17.2025) Dr. Jack Cush reviews the news and journal reports, discusses pediatric reports, pregn https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john… Tue,
Rheumatology
Congress reintroduces Safe Step Act
Physicians and patient advocacy groups are rallying behind a renewed legislative effort in Congress to amend what they claim are
RheumNow
SGLT-2 inhibitors and the prevention of autoimmune rheumatic disease
SGLT-2 inhibitors and the prevention of autoimmune rheumatic disease jjcush@gmail.com Tue, 10/21/2025 – 08:00
Google News
Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American College of …
… , at the 2025 American College of Rheumatology Convergence, being held October 24–29, 2025, in Chicago.
Google News
Atom Therapeutics to Present Positive Data from Clinical Trials of Its Lead Novel Oral Drugs …
… Rheumatology’s ACR Convergence 2025, October 24 – 29, 2025, in Chicago. The abstract titled, “A Phase 2a Study to
Google News
Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American College … – Stock Titan
… Rheumatology Convergence on October 27, 2025, presented by Dr. Gregory Sullivan.The poster title reports that TNX-102 SL/Tonmya demonstrated pain …
Science Direct
Coronary polyarteritis nodosa
Publication date: November 2025 Source: The Lancet Rheumatology, Volume 7, Issue 11 Author(s): Yi-Ning Yen, Hsien-Tzung Liao